Simply Wall St.
How Investors Are Reacting To Incyte (INCY) Winning EU Approval For Zynyz In Advanced Anal Cancer
📊
AI Sentiment
Positive
7/10
- Home
- INCY
INCY
Incyte Corp.
as of 03-13-2026 3:44pm EST
$92.08
+$0.05
+0.05%
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 17.0B | IPO Year: | 1994 |
| Target Price: | $101.10 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 22 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 6.41 | EPS Growth: | 4173.33 |
| 52 Week Low/High: | $53.56 - $112.29 | Next Earning Date: | 05-12-2026 |
| Revenue: | $3,394,635,000 | Revenue Growth: | 13.67% |
| Revenue Growth (this year): | 10.97% | Revenue Growth (next year): | 10.24% |
| P/E Ratio: | 14.35 | Index: | |
| Free Cash Flow: | N/A | FCF Growth: | +443.87% |
AI-Powered INCY Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 73.91%
73.91%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Incyte Corp. (INCY)
CAGNONI PABLO J
Sell
President, R&D
INCY Feb 19, 2026
Avg Cost/Share
$100.91
Shares
18,668
Total Value
$1,883,787.88
Owned After
234,800
SEC Form 4
Issa Mohamed Khairie
Sell
EVP, Head of US Oncology
INCY Jan 7, 2026
Avg Cost/Share
$109.07
Shares
10,856
Total Value
$1,184,063.92
Owned After
66,132
SEC Form 4
Stein Steven H
Sell
EVP & Chief Medical Officer
INCY Jan 5, 2026
Avg Cost/Share
$101.70
Shares
15,634
Total Value
$1,589,977.80
Owned After
34,203
SEC Form 4
Tray Thomas
Sell
Principal Accounting Officer
INCY Dec 19, 2025
Avg Cost/Share
$100.00
Shares
2,774
Total Value
$277,400.00
Owned After
22,973
SEC Form 4
Tray Thomas
Sell
Principal Accounting Officer
INCY Dec 18, 2025
Avg Cost/Share
$98.25
Shares
600
Total Value
$58,950.00
Owned After
22,973
SEC Form 4
Morrissey Michael James
Sell
EVP, Head of Tech. Operations
INCY Dec 17, 2025
Avg Cost/Share
$97.26
Shares
4,323
Total Value
$420,454.98
Owned After
27,507
SEC Form 4
Morrissey Michael James
Sell
EVP, Head of Tech. Operations
INCY Dec 16, 2025
Avg Cost/Share
$97.36
Shares
54,008
Total Value
$5,254,546.61
Owned After
27,507
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| CAGNONI PABLO J | INCY | President, R&D | Feb 19, 2026 | Sell | $100.91 | 18,668 | $1,883,787.88 | 234,800 | |
| Issa Mohamed Khairie | INCY | EVP, Head of US Oncology | Jan 7, 2026 | Sell | $109.07 | 10,856 | $1,184,063.92 | 66,132 | |
| Stein Steven H | INCY | EVP & Chief Medical Officer | Jan 5, 2026 | Sell | $101.70 | 15,634 | $1,589,977.80 | 34,203 | |
| Tray Thomas | INCY | Principal Accounting Officer | Dec 19, 2025 | Sell | $100.00 | 2,774 | $277,400.00 | 22,973 | |
| Tray Thomas | INCY | Principal Accounting Officer | Dec 18, 2025 | Sell | $98.25 | 600 | $58,950.00 | 22,973 | |
| Morrissey Michael James | INCY | EVP, Head of Tech. Operations | Dec 17, 2025 | Sell | $97.26 | 4,323 | $420,454.98 | 27,507 | |
| Morrissey Michael James | INCY | EVP, Head of Tech. Operations | Dec 16, 2025 | Sell | $97.36 | 54,008 | $5,254,546.61 | 27,507 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 10, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 10, 2026 · 100% conf.
AI Prediction BUY
1D
-0.01%
$100.04
Act: -1.21%
5D
+3.68%
$103.73
Act: +2.94%
20D
+3.32%
$103.37
Price: $100.05 Prob +5D: 100% AUC: 1.000
0000879169-26-000006
incy-20260210FALSE000087916900008791692026-02-102026-02-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2026
INCYTE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware001-1240094-3136539 (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
1801 Augustine Cut-Off Wilmington, DE 19803 (Address of principal executive offices)(Zip Code)
(302) 498-6700 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of exchange on which registered Common Stock, $.001 par value per shareINCYThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b—2 of the Securities Exchange Act of 1934 (§ 240.12b—2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On February 10, 2026, Incyte Corporation issued a press release announcing financial results for its fourth fiscal quarter and year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits.
ExhibitsDescription 99.1Press release issued by Incyte Corporation dated February 10, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 10, 2026
INCYTE CORPORATION
By:/s/ THOMAS TRAY Thomas Tray Vice President and Chief Accounting Officer (Principal Financial Officer and Principal Accounting Officer)
3
2025 Q3 Q3 2025 Earnings
8-K Oct 28, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 28, 2025
0000879169-25-000115
incy-20251028FALSE000087916900008791692025-10-282025-10-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2025
INCYTE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware001-1240094-3136539 (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
1801 Augustine Cut-Off Wilmington, DE 19803 (Address of principal executive offices)(Zip Code)
(302) 498-6700 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of exchange on which registered Common Stock, $.001 par value per shareINCYThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b—2 of the Securities Exchange Act of 1934 (§ 240.12b—2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On October 28, 2025, Incyte Corporation issued a press release announcing financial results for its third fiscal quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits.
ExhibitsDescription 99.1Press release issued by Incyte Corporation dated October 28, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 28, 2025
INCYTE CORPORATION
By:/s/ THOMAS TRAY Thomas Tray Vice President and Chief Accounting Officer (Principal Financial Officer and Principal Accounting Officer)
3
2025 Q2 Q2 2025 Earnings
8-K Jul 29, 2025
2025
Q2
Q2 2025 Earnings
8-KJul 29, 2025
0000879169-25-000100
incy-20250729FALSE000087916900008791692025-07-292025-07-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025
INCYTE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware001-1240094-3136539 (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
1801 Augustine Cut-Off Wilmington, DE 19803 (Address of principal executive offices)(Zip Code)
(302) 498-6700 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of exchange on which registered Common Stock, $.001 par value per shareINCYThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b—2 of the Securities Exchange Act of 1934 (§ 240.12b—2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On July 29, 2025, Incyte Corporation issued a press release announcing financial results for its second fiscal quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits.
ExhibitsDescription 99.1Press release issued by Incyte Corporation dated July 29, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 29, 2025
INCYTE CORPORATION
By:/s/ Christiana Stamoulis Christiana Stamoulis Executive Vice President and Chief Financial Officer
3
Latest Incyte Corp. News
INCY Breaking Stock News: Dive into INCY Ticker-Specific Updates for Smart Investing
Zacks
Incyte (INCY) Down 4.2% Since Last Earnings Report: Can It Rebound?
➖
AI Sentiment
Neutral
4/10
Zacks
INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
Incyte Says FDA Declines Supplemental Biologics Application for Zynyz Injection
📉
AI Sentiment
Negative
2/10
Compare INCY vs Leading Stocks
See how INCY stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "INCY Incyte Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.